SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ:CELG) today announced the appointment of Dr. Alise Reicin to President, Global Clinical Development, reporting to Mark J. Alles, Chairman and Chief Executive Officer, effective November 1, 2018. In this role, Dr. Reicin will be responsible for all aspects of mid- to late-stage clinical development across Celgene’s portfolio and will serve on the company's Executive Committee.
“Dr. Reicin is an accomplished physician with an excellent record of developing important therapeutics for multiple cancer and inflammatory indications,” said Mark J. Alles, Chairman and CEO of Celgene Corporation. “Led by Alise, our clinical development organization will be structured to more completely align with our strategy and mission to discover, develop and commercialize innovative therapies for patients with unmet need. She joins Dr. Rupert Vessey, President, Research & Early Development, and Dr. Jay Backstrom, Chief Medical Officer, as we deliver the potential of our deep and broad pipeline.”
The appointment of Dr. Reicin is part of a deliberate strategy to strengthen Celgene for long-term success. This organizational change further establishes clinical development as another center of excellence and enhances strategic leadership in discovery, development and commercialization. Dr. Rupert Vessey continues to lead early research and development. Dr. Reicin will lead mid- to late-stage clinical development, clinical operations, biostatistics, project leadership and project management. Dr. Jay Backstrom maintains responsibility for our global regulatory strategy, drug safety, regulatory operations and pharmacovigilance. Nadim Ahmed and Terrie Curran continue to lead our global commercial and medical affairs organizations for the Hematology & Oncology and Inflammation & Immunology franchises, respectively.
Dr. Reicin was most recently Senior Vice President and Head of Global Clinical Development in Research and Development (R&D) at EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany. In this role, she has been responsible for the clinical development of assets across oncology and inflammatory indications, including anti-PD-L1 avelumab in solid tumors and cladribine in relapsing multiple sclerosis. Since joining EMD Serono in 2015, she has led clinical development, biostatistics, clinical operations, and the Japan and China R&D hubs. Prior to joining EMD Serono, Dr. Reicin served as Vice President, Project and Pipeline Leadership, Oncology Franchise at Merck, Sharp & Dohme (Merck). She led Merck’s immuno-oncology program and oversaw initial development and filing activities worldwide, including the first approval for pembrolizumab (KEYTRUDA®) in the United States. Before joining Merck, Dr. Reicin was a faculty member at Columbia Medical School, and a physician and researcher at Columbia Presbyterian Hospital. She has a degree in biochemistry from Barnard College of Columbia University. She received her Medical Degree from Harvard Medical School, where she was enrolled in the Health Sciences and Technology program with MIT (Massachusetts Institute of Technology).
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. For more information, please visit www.celgene.com. Follow Celgene on Social Media: @Celgene, Pinterest, LinkedIn, Facebook and YouTube.
Hyperlinks are provided as a convenience and for informational purposes only. Celgene bears no responsibility for the security or content of external websites.
This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," "outlook" and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.